Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer
Standard
Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer. / Aziz, Atiqullah; Kempkensteffen, Carsten; May, Matthias; Lebentrau, Steffen; Burger, Maximilian; Chun, Felix K-H; Brookman-May, Sabine.
In: EXPERT REV ANTICANC, Vol. 15, No. 6, 06.2015, p. 649-66.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer
AU - Aziz, Atiqullah
AU - Kempkensteffen, Carsten
AU - May, Matthias
AU - Lebentrau, Steffen
AU - Burger, Maximilian
AU - Chun, Felix K-H
AU - Brookman-May, Sabine
PY - 2015/6
Y1 - 2015/6
N2 - Several novel therapeutic agents have demonstrated improvement of overall survival and further patient relevant endpoints in the setting of castration-resistant prostate cancer. Nevertheless, two questions have become increasingly relevant: are there any prognostic or predictive markers that could ease clinical decision-making using risk stratification and risk-adapted treatment in order to provide a benefit for the patient? Furthermore, against the background of increasing possibilities of therapy sequencing in clinical practice and in the clinical trial landscape in castration-resistant prostate cancer, does an isolated evaluation of overall survival reliably mirror the benefit attributable to a single compound? To address both these questions, suitable parameters serving as surrogates for intermediate and long-term endpoints and reflecting individual benefit, respectively, need to be identified and proven.
AB - Several novel therapeutic agents have demonstrated improvement of overall survival and further patient relevant endpoints in the setting of castration-resistant prostate cancer. Nevertheless, two questions have become increasingly relevant: are there any prognostic or predictive markers that could ease clinical decision-making using risk stratification and risk-adapted treatment in order to provide a benefit for the patient? Furthermore, against the background of increasing possibilities of therapy sequencing in clinical practice and in the clinical trial landscape in castration-resistant prostate cancer, does an isolated evaluation of overall survival reliably mirror the benefit attributable to a single compound? To address both these questions, suitable parameters serving as surrogates for intermediate and long-term endpoints and reflecting individual benefit, respectively, need to be identified and proven.
KW - Antineoplastic Agents
KW - Biomarkers, Tumor
KW - Endpoint Determination
KW - Humans
KW - Male
KW - Prognosis
KW - Prostatic Neoplasms, Castration-Resistant
KW - Risk Assessment
KW - Survival Rate
KW - Journal Article
KW - Review
U2 - 10.1586/14737140.2015.1038247
DO - 10.1586/14737140.2015.1038247
M3 - SCORING: Journal article
C2 - 25905802
VL - 15
SP - 649
EP - 666
JO - EXPERT REV ANTICANC
JF - EXPERT REV ANTICANC
SN - 1473-7140
IS - 6
ER -